This article is featured in the September issue of Drug Metabolism and Disposition available now:
Identification of Flavin-Containing Monooxygenase 5 (FMO5) as a Regulator of Glucose Homeostasis and a Potential Sensor of Gut Bacteria
FMO5 is identified here as a potential novel therapeutic target for obesity and insulin resistance. Flavin monooxygenase 5 (FMO5) knockout mice gain less weight, store less fat in white adipose tissue, have lower plasma concentrations of glucose and cholesterol, and enhanced whole-body energy expenditure compared to wild type mice. Here, Scott and provide evidence for FMO5 as a regulator of body weight and of glucose disposal and insulin sensitivity, possibly involving a role as a sensor of the gut microbiota. Read the full article.